M
98.94
1.28 (1.31%)
| Previous Close | 97.66 |
| Open | 98.41 |
| Volume | 380,800 |
| Avg. Volume (3M) | 570,908 |
| Market Cap | 5,821,095,424 |
| Price / Earnings (TTM) | 48.74 |
| Price / Earnings (Forward) | 26.88 |
| Price / Sales | 4.31 |
| Price / Book | 4.20 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 - 2 May 2025 |
| Profit Margin | 8.87% |
| Operating Margin (TTM) | 11.21% |
| Diluted EPS (TTM) | 2.03 |
| Quarterly Revenue Growth (YOY) | 9.40% |
| Quarterly Earnings Growth (YOY) | 1.20% |
| Total Debt/Equity (MRQ) | 57.61% |
| Current Ratio (MRQ) | 4.27 |
| Operating Cash Flow (TTM) | 220.80 M |
| Levered Free Cash Flow (TTM) | 179.41 M |
| Return on Assets (TTM) | 4.20% |
| Return on Equity (TTM) | 9.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Merit Medical Systems, Inc. | Bullish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.10 |
|
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 2.56% |
| % Held by Institutions | 105.74% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 127.00 (Canaccord Genuity, 28.36%) | Buy |
| Median | 116.00 (17.24%) | |
| Low | 110.00 (Raymond James, 11.18%) | Buy |
| Average | 116.17 (17.42%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 101.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 26 Feb 2025 | 111.00 (12.19%) | Buy | 100.45 |
| 29 Jan 2025 | 115.00 (16.23%) | Buy | 108.48 | |
| Canaccord Genuity | 26 Feb 2025 | 127.00 (28.36%) | Buy | 100.45 |
| 29 Jan 2025 | 128.00 (29.37%) | Buy | 108.48 | |
| Needham | 26 Feb 2025 | 116.00 (17.24%) | Buy | 100.45 |
| 29 Jan 2025 | 122.00 (23.31%) | Buy | 108.48 | |
| Wells Fargo | 26 Feb 2025 | 117.00 (18.25%) | Buy | 100.45 |
| Piper Sandler | 29 Jan 2025 | 116.00 (17.24%) | Buy | 108.48 |
| 21 Jan 2025 | 114.00 (15.22%) | Buy | 104.40 | |
| Raymond James | 31 Dec 2024 | 110.00 (11.18%) | Buy | 96.72 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Mar 2025 | Announcement | Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership |
| 10 Mar 2025 | Announcement | First Patient Enrolled in Merit Medical’s PREEMIE Study |
| 25 Feb 2025 | Announcement | Merit Medical Reports Fourth Quarter and Full Year 2024 Results and Issues Fiscal Year 2025 Guidance |
| 13 Jan 2025 | Announcement | Merit Medical Announces Preliminary Unaudited Revenue for the Year Ended December 31, 2024 and Plans to Announce Fourth Quarter and Year End 2024 Results and Issue Fiscal Year 2025 Guidance on February 25, 2025 |
| 20 Dec 2024 | Announcement | Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |